Radiofrequency catheter ablation of posteroseptal accessory pathways--results of a step-by-step ablation approach.

INTRODUCTION: Transcatheter radiofrequency ablation of posteroseptal accessory pathways (AP) is challenging. A number of different interventional approaches have been suggested by different groups. The selection of the initial approach is crucial in order to reduce radiation exposure and the number of unsuccessful lesions applied. We present our ablation technique as guided by a simplified electrocardiographic analysis of the delta wave polarity and the electrophysiologic mapping results. METHODS AND RESULTS: Out of 35 manifest APs encountered in the right (n=17) or the left posteroseptum (n=18) in 35 patients, 34 were successfully ablated. Despite their left sided location, 7 of the 18 "left" sided APs were ablated after switching from an initial arterial to a venous approach looking for an appropriate target site in the right posteroseptal space or within the coronary sinus network. The other 11 left sided APs were ablated in the mitral ring, on 2 occasions, on their atrial aspect through a retrograde transmitral approach. On the contrary, 16 of the 17 "right" sided APs were successfully ablated exclusively through a venous approach. Fourteen of these were ablated in the right posteroseptum, in 2 cases, only after reaching their ventricular aspect. Two right sided APs were interrupted in the coronary sinus os and the middle cardiac vein respectively. CONCLUSION: It appears that even though the electrocardiographic and electrophysiologic location of the AP in the posteroseptal space helps select the appropriate initial approach, it does not always guarantee a successful ablation procedure in the expected site of the corresponding atrioventricular ring. Not uncommonly, it will be necessary to look after intermediate target sites within the coronary sinus to improve the overall ablation success rate.

Predictors of ventricular tachycardia recurrence in 100 patients receiving tiered therapy defibrillators.

BACKGROUND AND HYPOTHESIS: Programmed electrical stimulation (PES) is a time-honored diagnostic tool in patients with ventricular tachyarrhythmias. The response to PES can be used to assess efficacy of pharmacologic or electrical therapy, as well as to obtain prognostic information. Reproducible induction of ventricular tachycardia with invasive electrophysiologic testing, or stimulation through defibrillator lead systems, can help optimize antiarrhythmic drug therapy and device programming during clinical follow-up. METHODS: We present our experience with 100 patients who had inducible sustained monomorphic ventricular tachycardia (SMVT) during invasive PES at baseline, and received a third-generation implantable cardioverter-defibrillator (ICD) alone, or in combination with antiarrhythmic drug therapy. Noninvasive programmed stimulation (NIPS) was performed prior to hospital discharge in 61 patients. RESULTS: The inducibility of SMVT was concordant between the invasive study and NIPS in a subgroup of 40 (82%) patients who had invasive PES on the same drug regimen. During a mean follow-up of 16 months, there were 12 nonarrhythmic deaths and recurrence of spontaneous SMVT in 36 (40%) of the surviving patients. Using a Cox proportional hazards model, the following variables were associated with early arrhythmia recurrence: persistent inducibility of SMVT during the NIPS session (relative risk 11, range 2.6-47); induction of SMVT with a cycle length > 280 ms during invasive baseline PES (2.5, 1.2-5) and presence of prior inferior myocardial infarction (2.1, 1-4.2). Timing to initial recurrence of spontaneous tachycardia was unaffected by other clinical variables or concomitant antiarrhythmic drug use. CONCLUSION: Programmed electrical stimulation techniques offer insight into the patterns of spontaneous ventricular tachycardia recurrence and have significant practical utility in the management of patients receiving third-generation ICDs.

Subpectoral cardioverter-defibrillator implantation using a lateral approach.

INTRODUCTION: Third-generation cardioverter-defibrillators have revolutionized management of ventricular tachyarrhythmias. Implantation can be performed in the electro-physiology laboratory, with minimal morbidity. Generator size has shrunk to the point that subcutaneous implantation is feasible and safe, even under local anesthesia. The prepectoral technique, however, is associated with increased mechanical stress to the subcutaneous tissue and can predispose to device erosion or infection. These complications may be avoided by submuscular placement. Among subpectoral techniques, the lateral approach offers unrestricted ability to deploy patches or array electrodes, should the need arise, and may represent the optimal implant technique under some circumstances. METHODS: We studied 29 male patients, aged 29-78 years, who presented with syncope or sustained ventricular tachycardia, and underwent subpectoral defibrillator implantation under general anesthesia or conscious sedation. All devices were third-generation active can systems with biphasic shock capability. Six dual-chamber defibrillators were used. RESULTS: Subpectoral implantation was successful in all cases, with an estimated blood loss of 28+/-17 mL and no immediate complications. Except for one patient who developed twiddler's syndrome and ultimately required revision to a subcutaneous pocket, the implant site was tolerated well, and no limitation in the range of motion of the upper limb was observed during 20 months of follow-up. CONCLUSIONS: Subpectoral implantation using a lateral approach is technically straightforward and can be applied globally, with modest additional resource and equipment requirements. Familiarity with this approach can maximize the likelihood of successful defibrillator implantation in the electrophysiology laboratory.

Correlation waveform analysis to discriminate monomorphic ventricular tachycardia from sinus rhythm using stored electrograms from implantable defibrillators.

In order to examine whether a template-matching program utilizing correlation waveform analysis (CWA) might be used to discriminate monomorphic ventricular tachycardia (MMVT) from sinus rhythm (SR) in patients with implantable cardioverter defibrillators (ICDs), we studied stored episodes of induced MMVT in 25 patients and compared them to corresponding stored SR electrograms. We calculated mean correlation coefficients for SR beats against an SR template chosen within each sinus episode, induced MMVT beats against an induced MMVT template within each ventricular tachycardia episode, and induced MMVT beats against the original SR template. For each patient, the 99.5% lower confidence limit for the mean correlation coefficient of SR beats versus an SR template (patient-specific method) or the empirical correlation coefficient value 0.9 were selected as threshold values to discriminate induced MMVT from SR. The mean correlation coefficient for induced MMVT beats versus the original SR template for each patient was subtracted from both threshold values. A positive value is defined as accurate discrimination of induced MMVT from SR. Using 0.9 for a threshold cut off, 21 of 25 episodes of induced MMVT were accurately labeled with a sensitivity of 84%. Using the patient-specific method, we were able to correctly distinguish 23 of 25 episodes of induced MMVT from SR with a sensitivity of 92%. There was no statistically significant difference between the patient-specific or empirical methods in detecting MMVT (P 50.4). This is the first demonstration using stored intracardiac electrograms from ICDs that CWA is able to discriminate MMVT from SR with high sensitivity. Such a template-matching system may be used for off-line analysis or real-time rhythm discrimination.

Transcoronary ethanol ablation of the atrioventricular node in a young patient with tricuspid atresia.

Catheter ablation of AV conduction with radiofrequency energy can be challenging in the presence of structural abnormalities of the AV junction, either congenitally or after reconstructive surgery. We used transcoronary ethanol to ablate the AV node in a patient with classic tricuspid atresia and refractory intraatrial reentry tachycardia. This approach provides an alternative means of creating complete heart block with catheter-based techniques, when radiofrequency catheter ablation is technically impossible or ineffective.

High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias.

OBJECTIVES: This study evaluates the hypothesis that in patients with syncope of unknown origin, inducible ventricular arrhythmias are specific arrhythmias and therefore should be appropriately treated. BACKGROUND: Although syncope is a common clinical entity, the evaluation and treatment of patients with syncope without a clear etiology are not well defined. Many patients with syncope of undetermined origin undergo invasive electrophysiologic evaluation. Abnormalities of the sinus node, prolongation of conduction times or inducible arrhythmias found at these evaluations are usually assumed to be the cause of syncope and are therefore treated. However, whether tachyarrhythmias are truly the cause of syncope, and whether treatment of these tachyarrhythmias can prevent recurrent syncope and arrhythmic death, is unknown. METHODS: This study included 50 consecutive patients with syncope of undetermined origin, ventricular tachyarrhythmias at electrophysiologic evaluation and treatment with an implantable cardioverter-defibrillator. RESULTS: Ventricular stimulation led to sustained monomorphic ventricular tachycardia in 36 patients, nonsustained ventricular tachycardia in 5 and ventricular fibrillation in 9. Over a 23 +/- 15-month (mean +/- SD) follow-up period, 18 patients received appropriate implantable cardioverter-defibrillator shock. Actuarial probability of appropriate therapy was 22% at 1 year and 50% at 3 years. Recurrent syncope was seen in five patients, three of whom had appropriate defibrillatory detections at the time of syncope. Four patients died (sudden death in one, congestive heart failure in two). CONCLUSIONS: In patients with syncope of undetermined origin and inducible ventricular tachyarrhythmias, appropriate implantable cardioverter-defibrillator therapy is common at follow-up. Sudden cardiac death is uncommon. This low incidence of sudden cardiac death and high incidence of appropriate defibrillator therapy support the current practice of using implantable cardioverter-defibrillators in patients with syncope of unknown origin and inducible ventricular arrhythmias.

Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators.

Arrhythmogenic right ventricular dysplasia is a clinical entity characterized by fatty infiltration of the right ventricle and left bundle morphology ventricular tachycardia occurring in young patients. The most common cause of death is tachyarrhythmic. Pharmacological and nonpharmacological therapies, including implantable cardioverter defibrillators, have been used to treat the arrhythmias. However, right ventricular endocardial leads in this population may be associated with an increased risk of perforation and suboptimal sensing and defibrillation efficacy due to the diseased right ventricle. We report on 12 patients with arrhythmogenic right ventricular dysplasia who were treated with implantable cardioverter defibrillators. The mean age was 31 +/- 9 years (range 15-48). Patients presented with presyncope (5), syncope (4), or cardiac arrest (3). All patients had electrocardiographic abnormalities characteristic of the condition. During programmed electrical stimulation nine patients had sustained ventricular tachycardia, while three patients had no inducible arrhythmia. Transvenous leads were placed in nine patients. In these patients pacing thresholds were significantly higher, R-wave amplitudes were significantly lower and defibrillation thresholds were not significantly different than in a cohort of patients without right ventricular dysplasia. There were no acute or chronic complications of right ventricular lead placement. Follow-up averaged 22 +/- 13 months (range 1-45). There was one sudden death at 1 month of follow-up. Of the 12 patients, 8 have had appropriate therapy delivered by the implantable defibrillator. Six patients are currently on sotalol to reduce the frequency of implantable defibrillator discharges. In conclusion, implantable cardioverter defibrillators with nonthoracotomy leads are feasible and safe in patients with arrhythmogenic right ventricular dysplasia. The frequency of appropriate therapy is high, supporting the use of implantable cardioverter defibrillators in this population.

Usefulness of electrophysiologic studies for new-onset sustained ventricular tachyarrhythmias shortly after coronary artery bypass grafting.

We retrospectively studied a group of 17 patients who developed life-threatening ventricular tachyarrhythmias shortly after coronary artery bypass grafting. The initial clinical event was sustained monomorphic ventricular tachycardia (VT) in 15 and ventricular fibrillation (VF) in 2, occurring at an average of 3.6 days postoperatively. All patients underwent electrophysiologic testing, with sustained monomorphic tachyarrhythmias inducible in 7. Three early deaths occurred after this initial evaluation. Among the 9 survivors with nonsustained, nonclinical or noninducible VT, 4 received no antiarrhythmic therapy and remained free of recurrence, whereas of the 5 that received drugs, implantable defibrillators, or both, 2 had spontaneous recurrence. For the surviving subgroup with inducible monomorphic VT, serial drug testing culminated in maintenance therapy with class IA agents or amiodarone, whereas defibrillators were also implanted in 3 patients. Overall, recurrence of life-threatening tachyarrhythmias beyond the immediate postoperative period was seen in 40% of patients with monomorphic clinical tachycardias and inducible sustained monomorphic VT. Ventricular tachyarrhythmias appearing shortly after cardiac surgery demonstrate significant chronicity and resistance to antiarrhythmic drug therapy, while statistically significant predictors of inducibility or their recurrence remain undefined.

Undersensing as a consequence of lead incompatibility: case report and a plea for universality.

Implantation of a single chamber bipolar pulse generator was complicated by transient loss of ventricular sensing, caused by mechanical damage to the unipolar lead connected to the system. A perforation of the insulating sheath was found at the site of the proximal connector block, and undersensing resolved after restoring its integrity with silicone adhesive. The ability to attach an unprotected unipolar lead to a bipolar connector, shared by the Voluntary (VS-1) and International (IS-1) designs, invites the possibility of injury to the insulating sheath by accidental tightening of the proximal screw. There is thus an urgent need for the development and universal adoption of a robust interface standard in lead connector design.